We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

FAPON

  Silver Fapon is a global IVD raw materials & one-stop solutions company offering 700+ reagent raw materials for the applicat... read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
27 Oct 2021 - 29 Oct 2021

Fapon Biotech Introduces World’s First COVID-19 Antibodies for Antigen Lateral Flow Testing in Differentiating Variant B.1.1.7 and Wild-Type Virus

By LabMedica International staff writers
Posted on 29 Sep 2021
Print article
Illustration
Illustration

Fapon Biotech Inc. (Guangdong, China) introduced the world’s first COVID-19 antibodies for antigen lateral flow testing in differentiating variant B.1.1.7 and wild-type virus at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo.

This year more than 35,000 industry leaders and professionals came together at the Georgia World Congress Center in Atlanta for AACC 2021. Fapon provides global diagnostic companies with high-performance IVD reagent raw materials, such as antigens, antibodies, and enzymes, as well as reagent solutions and innovative open instrument platforms.

At AACC 2021, Fapon introduced pioneering COVID-19 antibodies for antigen lateral flow testing to detect and differentiate COVID-19 and the most notable variant B.1.1.7 (also known as SARS-CoV-2 VUI 202012/01) in human samples. Variant strain surveillance is vital for COVID-19 control. Variants such as B.1.1.7 that causes 40-70% higher transmissibility and false-negative results on some PCR tests had drawn concerns and investigation from scientists and healthcare authorities like WHO, FDA and others.

The innovative COVID-19 Variant B.1.1.7 POCT Solution consists of a monoclonal antibody pair to differentiate the SARS-CoV-2 wild-type strain and the B.1.1.7 variant strain N protein. The antibody pair uses two different antibodies for immunoassay of test samples. These antibody pairs can detect B.1.1.7 and B.1.351 variants while having a consistent reaction to the wild-type virus. With the advantages of rapidity, low cost and high efficiency, this product can ensure the rapid and accurate detection of the B.1.1.7 variant strain.

Fapon also showcased its One-Stop Solution for COVID-19 RT-PCR Test that provides the comprehensive reagents, components, materials required to simplify collection, transport, storage and detection of SARS-CoV-2. The solution allows biospecimens to be taken from the collection sites and transported to the hospitals and reference labs where viral RNA is extracted and detected by RT-PCR assays. Also on display at AACC 2021 was Fapon’s COVID-19 NAb Test Solution that provides alternative testing methods to gold standard live virus-based PRNT with high correlation in performances, solving the problems of requiring high laboratory safety level, long detection time and quantification.

In addition, Fapon highlighted its COVID-19 NAb (neutralizing antibody) Test Solution for Latex-Enhanced Immunoturbidimetry that provides alternative testing methods to gold standard live virus-based PRNT with high correlation in performances, solving the problems of requiring high laboratory safety level, long detection time and quantification. Fapon displayed its COVID-19 IgM & IgG Quality Control at the event. Fapon’s Anti-SARS-CoV-2 fully human RBD monoclonal antibody and N protein humanized monoclonal antibody outperform positive specimens by exhibiting higher stability, specificity and affinity. They are safe to handle with non-infectious, providing a valuable tool to reagent development, validation, and production.

Fapon also demonstrated the Shine i1000 Fully Automated CLIA Analyzer which has a throughput of up to 120 tests per hour and provides the first result in less than 15 minutes. It combines incubation, washing and detection in an all-in-one innovative design and its small size with a weight of less than 38 kg makes it ideal for different settings.

Related Links:
Fapon Biotech Inc.

Gold Supplier
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
New
Silver Supplier
Bench-Top Molecular Microarray System
NanoCHIP XL Analyzer
New
Respiratory Multiplex RT-PCR Kit
Respiratory Multiplex RT-PCR Kit
New
Static Concentrator
BJP 20 Static Concentrator

Print article

Channels

Hematology

view channel
Image: Psoriatic plaques, showing a silvery center surrounded by a reddened border (Photo courtesy of Jane Bianchi, BA)

Hematological Parameters Compared in Psoriasis Patients

Psoriasis is a chronic, immune-mediated disorder that can involve the skin and/or joints. Four clinical types of psoriasis are currently recognized: psoriasis vulgaris (PsV), pustular psoriasis (PP), erythrodermic... Read more

Microbiology

view channel
Illustration

Sysmex Inostics Launches New Ultra-Sensitive Leukemia Blood Test for Early Detection of Cancer Cells Following Initial Therapy

Sysmex Inostics (Baltimore, MD, USA) has developed a new CLIA-validated liquid biopsy test for the detection of Minimal Residual Disease (MRD) in Acute Myeloid Leukemia (AML) to better help in the fight... Read more

Technology

view channel
Image: QIAreach QuantiFERON-TB (Photo courtesy of QIAGEN N.V.)

Qiagen Launches Novel Tuberculosis Blood Test That Marks Quantum Leap from Traditional TB Skin Test

QIAGEN N.V. (Venlo, Netherlands) has announced the launch and CE marking of QIAreach QuantiFERON-TB test for tuberculosis (TB) infection, in order to help achieve global TB elimination targets by increasing... Read more

Industry

view channel
Image: GastroPanel Quick Test (Photo courtesy of Biohit Healthcare)

Biohit’s Innovative GastroPanel Quick Test Receives CE Mark

Biohit Healthcare’s (Helsinki, Finland) GastroPanel Quick Test, the latest innovation in its unique GastroPanel product family, is now CE marked. The GastroPanel Quick Test is intended for diagnosing... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.